4.3 Article

A Randomized Controlled Trial of Subcutaneous Nerve Stimulation for Back Pain Due to Failed Back Surgery Syndrome: The SubQStim Study

Journal

NEUROMODULATION
Volume 22, Issue 5, Pages 519-528

Publisher

WILEY
DOI: 10.1111/ner.12784

Keywords

Back pain; failed back surgery syndrome; peripheral nerve field stimulation; randomized controlled trial; subcutaneous stimulation

Funding

  1. Medtronic, Inc.

Ask authors/readers for more resources

Objectives To compare the effectiveness of peripheral nerve stimulation utilizing a subcutaneous lead implant technique-subcutaneous nerve stimulation (SQS) plus optimized medical management (SQS + OMM arm) vs. optimized medical management alone (OMM arm) in patients with back pain due to failed back surgery syndrome. Patients and Methods Patients were recruited from 21 centers, in Europe, Israel, and Australia. Eligible patients were randomized (1:1) to SQS + OMM or OMM arms. Those in the SQS arm were implanted with a neurostimulator and up to two subcutaneous percutaneous cylindrical leads in the area of pain. Patients were evaluated pre-randomization and at one, three, six, and nine months post-randomization. The primary endpoint was the proportion of subjects with a >= 50% reduction in back pain intensity (responder) from baseline to nine months. Secondary outcomes included proportion of responders with a >= 50% reduction in back pain intensity at six months and >= 30% reduction at nine months, and the mean change from baseline in back pain intensity at six and nine months between the two arms. Results Due to the slow rate of recruitment, the study was terminated early with 116 subjects randomized. A total of 33.9% (19/56, missing: n = 20 [36%]) of subjects in the SQS + OMM arm and 1.7% (1/60, missing: n = 24 [40%]) in the OMM arm were responders at Month 9 (p < 0.0001). Secondary objectives showed a significant difference in favor of SQS + OMM arm. Conclusion The results indicate that the addition of SQS to OMM is more effective than OMM alone in relieving low back pain at up to nine months.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

High-Dose Spinal Cord Stimulation Reduces Long-Term Pain Medication Use in Patients With Failed Back Surgery Syndrome Who Obtained at Least 50% Pain Intensity and Medication Reduction During a Trial Period: A Registry-Based Cohort Study

Lisa Goudman, Ann De Smedt, Patrice Forget, Sam Eldabe, Maarten Moens

Summary: High-dose spinal cord stimulation (HD-SCS) shows significant and sustained reduction in pain medication use for patients with failed back surgery syndrome (FBSS), especially in neurostimulation-naive patients.

NEUROMODULATION (2021)

Article Medicine, Research & Experimental

Analgesic Efficacy of Burst and Tonic (500 Hz) Spinal Cord Stimulation Patterns: A Randomized Placebo-Controlled Crossover Study

Sam Eldabe, Rui Duarte, Ashish Gulve, Heather Williams, Fay Garner, Morag Brookes, Grace Madzinga, Eric Buchser, Alan M. Batterham

Summary: The study compared the efficacy of burst and tonic sub-threshold stimulation at 500 Hz versus sham stimulation in reducing pain intensity in adult subjects with chronic back and leg pain using a spinal cord stimulation device. Results showed that T500 stimulation was significantly more effective than sham stimulation, while BST stimulation was practically equivalent to sham stimulation in patients habituated to tonic SCS.

NEUROMODULATION (2021)

Article Medicine, Research & Experimental

To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients' View From the TRIAL-STIM Randomized Controlled Trial

Raymond Chadwick, Rebekah McNaughton, Sam Eldabe, Ganesan Baranidharan, Jill Bell, Morag Brookes, Rui V. Duarte, Jenny Earle, Ashish Gulve, Rachel Houten, Susan Jowett, Anu Kansal, Shelley Rhodes, Jennifer Robinson, Sara Griffiths, Rod S. Taylor, Simon Thomson, Harbinder Sandhu

Summary: The preference for a one-stage SCS procedure was overwhelming among participants, both before and after implantation. Reasons for this preference included saving time, avoiding worries about loose wires, having only one recovery period, and saving healthcare resources. The qualitative study findings supported the results of the TRIAL-STIM RCT.

NEUROMODULATION (2021)

Review Clinical Neurology

Peripherally Induced Reconditioning of the Central Nervous System: A Proposed Mechanistic Theory for Sustained Relief of Chronic Pain with Percutaneous Peripheral Nerve Stimulation

Timothy R. Deer, Sam Eldabe, Steven M. Falowski, Marc A. Huntoon, Peter S. Staats, Isaac R. Cassar, Nathan D. Crosby, Joseph W. Boggs

Summary: PNS is an effective tool for chronic pain treatment, with recent studies showing sustained pain reduction and proposing a new theory for pain management.

JOURNAL OF PAIN RESEARCH (2021)

Article Medicine, Research & Experimental

Resource Use and Cost of Subcutaneous Nerve Stimulation Versus Optimized Medical Management in Patients With Failed Back Surgery Syndrome: An Analysis of the SubQStim Study

Colin Green, Sam S. Eldabe, Rod S. Taylor, Mehdi Zahra, Simon Eggington

Summary: The SubQStim study analyzed healthcare resource use and cost of FBSS patients receiving subcutaneous nerve field stimulation. The treatment group had significantly higher costs largely due to device acquisition/implantation, with potential benefits in reducing pain medication and healthcare visits. Further long-term cost-effectiveness analyses are needed to fully evaluate the benefits of stimulation.

NEUROMODULATION (2021)

Article Medicine, Research & Experimental

Cross-Country Differences in Pain Medication Before and After Spinal Cord Stimulation: A Pooled Analysis of Individual Patient Data From Two Prospective Studies in the United Kingdom and Belgium

Lisa Goudman, Rui Duarte, Ann De Smedt, Sue Copley, Sam Eldabe, Maarten Moens

Summary: The study analyzed differences in prescription practices of SCS implantation patients between Belgium and the United Kingdom, revealing that NSAIDs and neuropathic mood agents are more frequently used in the UK. After three months of SCS, a decrease in medication use is observed in both countries, with higher reductions in Belgium, presumably due to strict regulations concerning reimbursement criteria.

NEUROMODULATION (2021)

Article Anesthesiology

A prospective long-term follow-up of dorsal root ganglion stimulation for the management of chronic intractable pain

Sam Eldabe, Sue Copley, Ashish Gulve, Ganesan Baranidharan, Beatrice Bretherton, Anu Kansal, Grace Madzinga, Morag Brookes, Simon Thomson, Rui Duarte

Summary: This study aimed to report on the long-term follow-up of DRG stimulation for intractable chronic pain. The findings showed that DRG stimulation can effectively relieve pain and improve quality of life in patients suffering from neuropathic pain. However, there was a high revision rate within the first 24 months and some patients experienced shorter than expected battery life.
Article Anesthesiology

Cauda equina syndrome after unilateral medial branch blocks of the lower lumbar zygapophyseal joints

Zied Zaghdoudi, Sam Eldabe, Sue Copley, Haythem Abbes, Philippe Temperli, Eric Buchser

Summary: Medial branch blockade of the lumbar facet joints is generally considered safe, but a rare case of neurological damage occurred after the procedure, likely due to accidental intra-arterial injection of particulate methylprednisolone causing blockage and ischemia.

PAIN PRACTICE (2022)

Review Clinical Neurology

Biomarkers for Chronic Pain: Significance and Summary of Recent Advances

Sam Eldabe, Ilona Obara, Catherine Panwar, David Caraway

Summary: The development of biomarkers for chronic pain offers opportunities for better management and prevention. Despite some progress, there is still a need for further research and development.

PAIN RESEARCH & MANAGEMENT (2022)

Article Medicine, General & Internal

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews

Giovanni E. Ferreira, Christina Abdel-Shaheed, Martin Underwood, Nanna B. Finnerup, Richard Day, Andrew McLachlan, Sam Eldabe, Joshua R. Zadro, Christopher G. Maher

Summary: This study provides a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for different pain conditions. The results show that antidepressants are effective in some pain conditions, particularly proton pump inhibitors, postoperative pain, neuropathic pain, and fibromyalgia. However, there is insufficient evidence to support the efficacy of antidepressants in other pain conditions. A more nuanced approach is needed when prescribing antidepressants for pain conditions.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Review Anesthesiology

Does industry funding and study location impact findings from randomized controlled trials of spinal cord stimulation? A systematic review and meta-analysis

Sam Eldabe, Sarah Nevitt, Sue Copley, Michelle Maden, Lisa Goudman, Salim Hayek, Nagy Mekhail, Maarten Moens, Phillipe Rigoard, Rui Duarte

Summary: This study investigated the impact of industry funding and geographical location on spinal cord stimulation (SCS) therapy. The results showed no significant differences between industry-funded and non-industry-funded studies in terms of outcomes compared to usual care. However, pain intensity and comparisons between high-frequency SCS and low-frequency SCS seemed to be influenced by industry funding.

REGIONAL ANESTHESIA AND PAIN MEDICINE (2023)

Editorial Material Anesthesiology

Limitations of the Cochrane review of spinal cord stimulation for low back pain

Peter S. Staats, Rod S. Taylor, Christopher Gilligan, Samir Sheth, Kiran V. Patel, Rui V. Duarte, Sam Eldabe

PAIN PRACTICE (2023)

Review Anesthesiology

Painful diabetic polyneuropathy

Xander Zuidema, Bastiaan de Galan, Brigitte Brouwer, Steven Cohen, Sam Eldabe, Charles Argoff, Frank Huygen, Jan Van Zundert

Summary: Painful diabetic polyneuropathy (PDPN) is a common symptom in patients with diabetes, causing significant impact on quality of life. The diagnosis and treatment methods are evolving, focusing on precise pain-phenotyping and genotyping, as well as mechanism-based pharmacological treatments. Proper control of glucose levels and prevention of risk factors are essential in treatment.

PAIN PRACTICE (2023)

No Data Available